- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Akoya Biosciences Inc (AKYA)
Akoya Biosciences Inc stock price live, this page displays NASDAQ AKYA stock exchange data. View the AKYA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Akoya Biosciences Inc real time stock price chart below.
What Is the Akoya Biosciences Inc Stock Price Today?
The Akoya Biosciences Inc stock price today is 1.290.
What Is the Stock Symbol for Akoya Biosciences Inc?
The stock symbol for Akoya Biosciences Inc is ""AKYA.""
What Stock Exchange Does Akoya Biosciences Inc Trade On?
Akoya Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Akoya Biosciences Inc a Good Stock to Buy?
Determining whether Akoya Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKYA quote. (ISIN: US00974H1041)
What Is the Akoya Biosciences Inc Stock Price Today?
The Akoya Biosciences Inc stock price today is 1.290.
What Is the Stock Symbol for Akoya Biosciences Inc?
The stock symbol for Akoya Biosciences Inc is ""AKYA.""
What Stock Exchange Does Akoya Biosciences Inc Trade On?
Akoya Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Akoya Biosciences Inc a Good Stock to Buy?
Determining whether Akoya Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKYA quote. (ISIN: US00974H1041)
1.290
-0.070(-5.15%)
Real-time Data·
Fair Value
An estimate of a Akoya Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.290
1.640
52 wk Range
0.931
3.420
Showing Akoya Biosciences historical data. For real-time data please try another search
Fair Value
An estimate of a Akoya Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2901.640
52 wk Range
0.9313.420
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AKYA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Akoya Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Form 8K Akoya Biosciences Inc For: 8 July
- Investing.com
- Akoya Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 8K Akoya Biosciences Inc For: 8 July
- Investing.com
- Akoya Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Akoya Biosciences Inc Company Profile
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. As of July 8, 2025, Akoya Biosciences, Inc. operates as a subsidiary of Quanterix Corporation.
Akoya Biosciences Inc SWOT Analysis
Spatial Proteomics Pionee | Akoya Biosciences leads in high-parameter tissue analysis, facing challenges amid market growth. Explore its position in the evolving diagnostics landscape. |
Financial Hurdles | Delve into Akoya's recent performance setbacks, including revenue decline and lowered guidance. Learn about strategies to recapture missed opportunities. |
Competitive Dynamics | Examine how Akoya navigates increasing competition, particularly after Lunaphore's acquisition. Discover analysts' views on the company's ability to thrive. |
Future Outlook | Analyst price targets range from $6 to $8. Investigate Akoya's path to cash flow breakeven and its attractive valuation at 3x projected 2024 sales. |
Akoya Biosciences Inc Earnings Call Summary for Q3/2024
- Q3 revenue down 25% YoY to $18.8M; instrument revenue fell 53%, reagent revenue up 11% to $6.3M
- Gross margin improved to 62.3%; full-year revenue projected between $80M-$85M
- Transitioning to application-driven sales model; advancing companion diagnostic pipeline with biopharma partnerships
- Cash flow positivity now expected by mid-2025; strategic investments planned in commercial operations
- Clinical trial pipeline anticipated to significantly contribute to 2025 revenue
Last Updated: 15/11/2024, 10:34
Read Full TranscriptCompare AKYA to Peers and Sector
Metrics to compare | AKYA | Peers Peers - average of corresponding metrics from companies closely matching AKYA: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAKYAPeersSector |
|---|---|---|---|---|
P/E Ratio | −1.4x | 0.0x | −0.5x | |
PEG Ratio | −0.04 | 0.00 | 0.00 | |
Price/Book | −10.9x | 0.0x | 2.6x | |
Price / LTM Sales | 0.8x | 0.0x | 3.3x | |
Upside (Analyst Target) | −16.3% | 0.0% | 43.5% | |
Fair Value Upside | Unlock | 0.0% | 6.9% | Unlock |
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.32 / -0.21
Revenue / Forecast
16.60M / 19.56M
People Also Watch
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.